Literature DB >> 29344885

MicroRNA Networks in Breast Cancer Cells.

Andliena Tahiri1, Miriam R Aure2, Vessela N Kristensen3,4.   

Abstract

A variety of molecular techniques can be used in order to unravel the molecular composition of cells. In particular, the microarray technology has been used to identify novel biomarkers that may be useful in the diagnosis, prognosis, or treatment of cancer. The microarray technology is ideal for biomarker discovery as it allows for the screening of a large number of molecules at once. In this review, we focus on microRNAs (miRNAs) which are key molecules in cells and regulate gene expression post-transcriptionally. miRNAs are small, single-stranded RNA molecules that bind to complementary mRNAs. Binding of miRNAs to mRNAs leads either to degradation, or translational inhibition of the target mRNA. Roughly one third of all the mRNAs are postulated to be regulated by miRNAs. miRNAs are known to be deregulated in different types of cancer, including breast cancer, and it has been demonstrated that deregulation of several miRNAs can be used as biological markers in cancer. miRNA expression can for example discriminate between normal, benign and malignant breast tissue, and between different breast cancer subtypes.In the post-genomic era, an important task of molecular biology is to understand gene regulation in the context of biological networks. Because miRNAs have such a pronounced role in cells, it is pivotal to understand the mechanisms that underlie their control, and to identify how miRNAs influence cancer development and progression.

Entities:  

Keywords:  Biomarkers; Breast cancer; Cancer; Microarrays; Systems biology; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29344885     DOI: 10.1007/978-1-4939-7493-1_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Gene expression of adipokines and adipokine receptors in the tumor microenvironment: associations of lower expression with more aggressive breast tumor features.

Authors:  Adana A M Llanos; Song Yao; Amartya Singh; John B Aremu; Hossein Khiabanian; Yong Lin; Coral Omene; Angela R Omilian; Thaer Khoury; Chi-Chen Hong; Shridar Ganesan; David J Foran; Michael J Higgins; Christine B Ambrosone; Elisa V Bandera; Kitaw Demissie
Journal:  Breast Cancer Res Treat       Date:  2020-10-16       Impact factor: 4.872

2.  miR-6852 serves as a prognostic biomarker in colorectal cancer and inhibits tumor growth and metastasis by targeting TCF7.

Authors:  Bao-Hong Cui; Xuan Hong
Journal:  Exp Ther Med       Date:  2018-06-07       Impact factor: 2.447

3.  Upregulation of microRNA 344a-3p is involved in curcumin induced apoptosis in RT4 schwannoma cells.

Authors:  Eun Jung Sohn; Kyoung-Mi Bak; Yun-Kyeong Nam; Hwan Tae Park
Journal:  Cancer Cell Int       Date:  2018-12-04       Impact factor: 5.722

Review 4.  MicroRNA-34 family in breast cancer: from research to therapeutic potential.

Authors:  Saber Imani; Ray-Chang Wu; Junjiang Fu
Journal:  J Cancer       Date:  2018-09-28       Impact factor: 4.207

5.  lncRNA MNX1-AS1 Promotes Glioblastoma Progression Through Inhibition of miR-4443.

Authors:  Yan Gao; Yongchuan Xu; Jue Wang; Xue Yang; Lulu Wen; Juan Feng
Journal:  Oncol Res       Date:  2018-04-20       Impact factor: 5.574

6.  Exploring the Mechanism of Baicalin Intervention in Breast Cancer Based on MicroRNA Microarrays and Bioinformatics Strategies.

Authors:  Anqi Ge; Lifang Liu; Xian'guang Deng; Jun Luo; Yanghua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-20       Impact factor: 2.629

7.  MicroRNA‑3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.

Authors:  Taotao Shou; Huyin Yang; Jia Lv; Dai Liu; Xiaoyang Sun
Journal:  Mol Med Rep       Date:  2018-11-27       Impact factor: 2.952

Review 8.  MicroRNAs in Vascular Eye Diseases.

Authors:  Chi-Hsiu Liu; Shuo Huang; William R Britton; Jing Chen
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.